je.st
news
Tag: cancer
Cancer tech: reprogramming rogue cells in pancreatic cancers
2015-04-21 19:30:01| Extremetech
Researchers at the Sanford-Burnham Institute in San Diego have figured out a way to reprogram the rogue cells found in certain pancreatic cancers back into obedient cells.
Quest Diagnostics, French agency seek to expand breast cancer gene database
2015-04-21 09:33:22| Biotech - Topix.net
Quest Diagnostics Inc , the world's largest provider of diagnostic testing services, is working with France's national health agency to build an expanded database for BRCA1 and BRCA2 gene mutations to better determine patient hereditary risks of breast and ovarian cancer. Other medical testing companies and public laboratories can participate in the project, called BRCA Share, for which Quest will charge an annual fee in return for access to the curated database, Madison, New Jersey-based Quest said on Tuesday.
Tags: database
french
expand
agency
Mark Carnegie-backed biotech Minomic creates improved prostate cancer test
2015-04-20 04:30:55| Biotech - Topix.net
Minomic CEO Brad Walsh says the company's new prostate cancer test could be on sale before the end of the year. Biotechnology company Minomic has developed a simpler, more accurate blood test for diagnosing prostate cancer, which could reduce the number of men who go onto invasive follow up tests and suffer plenty of heartache after receiving an initial 'false positive' result.
Tags: test
mark
improved
cancer
Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
2015-04-19 14:30:00| Merck.com - Product News
Dateline City: PHILADELPHIA Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in nave and previously-treated patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
advanced
journal
published
Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2015-04-19 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
application
license
cell
Sites : [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] next »